Retrospective, Non-significant Risk, Deep Brain Stimulation (DBS) Care Management Software Study

This study has been completed.
Information provided by (Responsible Party):
MedtronicNeuro Identifier:
First received: December 11, 2012
Last updated: January 10, 2014
Last verified: January 2014

To evaluate DBS device settings and match with the features of the DBS care management software.

Condition Intervention
Parkinson's Disease
Device: Medtronic DBS system

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Optivise Map Concordance Study

Resource links provided by NLM:

Further study details as provided by MedtronicNeuro:

Primary Outcome Measures:
  • To characterize the percentage of leads where the target map and the clinically-derived activation map overlap [ Time Frame: 18 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in UPDRS III scores from baseline to follow-up. [ Time Frame: 18 months ] [ Designated as safety issue: No ]

Enrollment: 23
Study Start Date: November 2012
Study Completion Date: August 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Subjects with advanced Parkinson's disease
Subjects with advanced Parkinson's Disease implanted with Medtronic DBS system
Device: Medtronic DBS system
Patients implanted with the Medtronic DBS system due to their advanced Parkinson's disease


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Parkinson's disease patients who have been implanted with the DBS system


Inclusion Criteria:

  • Patient with Medtronic Deep Brain Stimulation therapy for idiopathic levodopa responsive Parkinson's Disease
  • Patient who has had lead placement in the Subthalamic nucleus
  • Patient with pre-op MRI available
  • Patient with post-op CT scan available showing placement of the lead
  • Patient who has documented improvement of at least 35% on UPDRS III scores from baseline preoperative off medication state compared to post DBS implant stimulation on/medications off

Exclusion Criteria:

  • Patient who has had clinically significant persistent stimulation related adverse effects
  • Patient who has evidence of lead migration without lead revision
  • Patient with other brain malformations that would make it difficult to process images (ablative surgery in the basal ganglia, resective surgery, brain tumor)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01750242

United States, California
Scripps Clinic, Division of Neurology
La Jolla, California, United States, 92037
United States, Kansas
Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
Sponsors and Collaborators
Principal Investigator: Rajesh Pahwa, MD Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center
Principal Investigator: Melissa Houser, MD Scripps Clinic Division of Neurology
  More Information

No publications provided

Responsible Party: MedtronicNeuro Identifier: NCT01750242     History of Changes
Other Study ID Numbers: 1669
Study First Received: December 11, 2012
Last Updated: January 10, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases processed this record on September 14, 2014